Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer

Pharmacopsychiatry

Volumn 30, Issue 6, 1997, Pages 266-270

  Joos, A A B ^a,d   Konig F ^a   Frank, U G ^a   Kaschka, W P ^a   Morike K E ^b   Ewald, R ^c  

^a UNIVERSITY OF ULM   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c Medical Department/CNS   (Germany)

^d Krankenhaus Stockach   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; PAROXETINE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CASE REPORT; DELUSION; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; FLUSHING; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SIDE EFFECT; VERTIGO;

EID: 0031467749     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979505     Document Type: Article

References (33)

1. Baldessarini, R. J., F. R. Frankenburg: Clozapine: A novel antipsychotic agent. N. Engl. J. Med. 324 (1991) 746-754
2. Bacher, N. M., P. Rushin: Addition of fluoxetine to treatment of schizophrenic patients. Am. J. Psychiatry 148 (1991) 274-275
3. Balant-Gorgia, A. E., C. Ries, L. P. Balant: Metabolic interaction between fluoxetine and clomipramine: a case report. Pharmacopsychiat. 29 (1996) 38-41
4. Barnett, W., C. Mundt, P. Richter: Primäre und sekundäre Negativsymptome: Eine sinnvolle Differenzierung? Nervenarzt 67 (1996) 558-563
5. Calabrese, J. R., S. E. Kimmel, M. J. Woyshville, D. J. Rapport, C. J. Faust, P. A. Thompson, H. Y. Meltzer: Clozapine tor treatment-refractory mania. Am. J. Psychiatry 153 (1996) 759-764
6. Carpenter, W. T., R. R. Conley, R. W. Buchanan, A. Breier, C. A. Tamminga: Patient response and ressource management: Another view of clozapine treatment in schizophrenia. Am. J. Psychiatry 152 (1995) 827-835
7. Centorrino, F., R. J. Baldessarini, J. Kando, F. R. Frankenburg, S. A. Volpicelli, P. R. Puopolo, J. C. Flood: Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine and valproate. Am. J. Psychiatry 151 (1994) 123-125
8. Centorrino, F., R. J. Baldessarini, F. R. Frankenburg, J. Kando, S. A. Volpicelli, J. G. Flood: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry 153 (1996) 820-822
9. Conus, P., G. Bondolfi, C.B. Eap, F. Macciardi, P. Baumann: Pharmacokinetic fluvoxamine - clomipramine interaction with favorable consequences in therapy-resistant depressive patient. Pharmacopsychiat. 29 (1996) 108-110
10. Cresteil, T., C. Celier, P. Kremers, J. P. Flinois, P. Bedune, J. P. Leroux: Induction of drug-metabolizing enzymes by tricyclic antidepressants in human liver: Characterization and partial resolution of cytochromes P-450. Br. J. Clin. Pharmac. 16 (1983) 651-657
11. Crewe, H. K., M. S. Lennard, G. T. Tucher, F. R. Woods, R. E. Haddock: The effect of paroxetine and other specific 5-HT reuptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br. J. Clin. Pharmacol. 32 (1991) 658 P-659 P
12. De Vane, C. L: Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry 55 (1994) 38-45
13. Finley, P. R.: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother. 28 (1994) 1359-1369
14. Fischer, V., B. Vogels, G. Manter, R. E. Tynes: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P 450 2D6. J. Pharmacol. Exp. Ther. 260 (1992) 1355-1360
15. Gatti, F., L. Bellini, M. Gasperini, J. Perez, R. Zanardi, E. Smeraldi: Fluvoxamine alone in the treatment of delusional depression. Am. J. Psychiatry 153 (1996) 414-416
16. Goff, D. C., A. W. Brotmann, M. Waites, S. McCormick: Trial of Fluoxetine added to neuroleptics for treatment-restistant schizophrenic patients. Am. J. Psychiatry 147 (1990) 492-494
17. Hale, A. S.: New antidepressants: use in high-risk patients. J. Clin. Psychiatry 54 (8 Suppl.) (1993) 61-70
18. Hiemke, C., H. Weigmann, S. Härtter, N. Dahmen, H. Wetzel, H. Müller: Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 14 (1994) 279-281
19. Hiemke, C., H. Weigmann, S. Härtter, A. Szegedi, I. Anghelescu: Combination of clozapine and SSRIs in schizophrenic patients. Eur. Neuropschopharmacol. 6 (Suppl. 3) (1996) 217
20. Kendler, K. S., W. M. Glazer, H. Morgenston: Dimensions in delusional experience. Am. J. Psychiatry 140 (1983) 466-469
21. Koponen, H. J., E. Leinonen, U. Lepola: Fluvoxamine increases the clozapine serum levels significantly. Eur. Neuropsychopharmacol. 6 (1996) 69-71
22. Möller, H. J.: Aktuelle Standards der Behandlung schizophrener Erkrankungen. Psychopharmakotherapie 2 (1996) 51-56
23. Mörike, K. E., D. M. Roden: Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin. Pharmacol. Ther. 58 (1994) 28-34
24. Müller-Spahn, F., S. Modell, M. Thomma: Neue Aspekte in der Diagnostik, Pathogenese und Therapie schizophrener Minussymptomatik. Nervenarzt 63 (1992) 383-400
25. Nemeroff, C. B., C. L. De Vane, B. G. Polloch: Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153 (1996) 311-320
26. Preskorn, S. H.: Sudden death and tricyclic antidepressants: a rare adverse event linked to high TCA plasma levels. Nord. J. Psychiatry 47 (1993) 49-55
27. Rechlin, T.: Die Auswirkungen der psychopharmakologischen Therapie auf die Herzfrequenzvariation. Nervenarzt 66 (1995) 678-685
28. Schönborn, H.: Hypotonie. In: Gross, R., P. Schölmerich, W. Gerok (Hrsg.): Lehrbuch der Inneren Medizin. Schattauer, Stuttgart New York, 7. Aufl. (1987) 415-418
29. Siris, S. G., F. Adan, M. Cohen, J. Mandeli, A. Aronson, E. Casey: Postpsychotic depression and negative symptoms: an investigation of syndromal overlaps. Am. J. Psychiatry 145 (1988) 1532-1537
30. Szegedi, A., H. Wetzel, J. Wiesner, C. Hiemke: Verbesserte Wirksamkeit und Verträglichkeit von Clozapin nach Zugabe von Fluvoxamin. Psychopharmakotherapie 2 (1995) 84-85
31. Toylor, D., M. Lader: Cytochromes and psychothropic drug interactions. Br. J. Psychiatry 168 (1996) 529-532
32. Wander Pharma: Leponex, Fachinformation. Wander Pharma GmbH, April 1996
33. Wolfersdorf, M., F. König, T. Barg: Paroxetinspiegel bei gleichzeitiger Gabe von Paroxetin und Zotepin. Psychopharmakotherapie 1 (1995) 12-14